S Duarte, BSc
NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality RatesNAFLD and New-Onset Heart Failure: What is the Link?
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?Adipose tissue insulin resistance and fibrosis stage in NASH
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Read MoreAdipose tissue insulin resistance and fibrosis stage in NASHHepatic Macrophages in NAFLD: A Novel Therapeutic Target?
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?MASLD: A New Fatty Liver Disease Nomenclature?
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Read MoreMASLD: A New Fatty Liver Disease Nomenclature?Measuring NAFLD Models of Care: A New Strategic Framework?
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Read MoreMeasuring NAFLD Models of Care: A New Strategic Framework?Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
Read MoreAdverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?NAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Read MoreNAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting DisparitiesDysregulations in Gut Microbiota Composition and Hepatic DNA Methylation in NAFLD: Is There a Link?
Patients with non-alcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiota composition. Indeed, both nuclear and mitochondrial DNA methylation have been linked to the development of NAFLD and metabolic diseases, including obesity and type 2 diabetes mellitus.
Read MoreDysregulations in Gut Microbiota Composition and Hepatic DNA Methylation in NAFLD: Is There a Link?Clinical outcome prediction in NAFLD: comparing non-invasive tools and liver histology
Previous studies investigating non-invasive tools for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, have demonstrated the clear diagnostic efficacy of liver stiffness measurement by vibration-controlled transient elastography (LSM-VCTE).
Read MoreClinical outcome prediction in NAFLD: comparing non-invasive tools and liver histologyBiomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.
Read MoreBiomarker Qualification for NAFLD and NASH: Insights from the LITMUS ConsortiumImproving NASH Clinical Trials: Barriers and Breakthroughs
Despite its global prevalence of 25%, no pharmacotherapies have yet been approved to treat non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), its inflammatory subtype.
Read MoreImproving NASH Clinical Trials: Barriers and BreakthroughsDr. S. Duarte graduated in Nutrition from the Universidade Paulista in 2007, got a Master in Clinical Gastroenterology Program at the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO in 2015 and became Doctor of Science in Gastroenterology from the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (2019) . He is currently a professor of undergraduate classes at Universidade Paulista. Has a background in nutrition, with a focus on gut microbiota assessment in Non-Alcoholic Fatty Liver Disease (NAFLD).
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES